论文部分内容阅读
尽管晚期头颈癌的传统治疗方法(外科、放疗和化疗)在不断进展,但最近几十年,在美国和全球范围内头颈癌治愈率仍无明显改善。虽然最近关于放、化疗同时进行的临床试验得出了鼓舞人心的结果,但大部分方案的毒性较大,不宜于在社区医院中推广。最近许多对头颈癌有潜在治疗价值的生物制剂正在进行临床试验,其中几种生物制剂已联合应用到高剂量的放疗中。本文目的是综述上述生物制剂联合放疗治疗晚期头颈癌的结果。另外,将简要报道几个与放疗有协同作用的新药物的临床前研究资料,这些或许是未来头颈癌治疗方案的重要组成部分。
Although the traditional treatment of advanced head and neck cancers (surgery, radiotherapy and chemotherapy) continues to advance, the cure rate of head and neck cancer in the United States and the world has not improved significantly in recent decades. Although recent clinical trials involving simultaneous radiotherapy and chemotherapy have yielded encouraging results, most of the regimens are more toxic and should not be promoted in community hospitals. Recently, many biological agents with potential therapeutic value for head and neck cancer are undergoing clinical trials, several of which have been applied in combination with high-dose radiation therapy. The purpose of this article is to review the results of the above biological agents combined with radiotherapy for advanced head and neck cancer. In addition, preclinical studies of several new drugs that work synergistically with radiotherapy will be briefly reported, which may be an important part of the treatment of head and neck cancers in the future.